{"id":"calcium-dobesilate-capsules","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Calcium dobesilate is a vascular protectant that acts on the microvasculature by reducing capillary permeability and fragility. It improves blood flow through microvessels by decreasing blood viscosity and increasing erythrocyte deformability, thereby enhancing oxygen delivery to tissues. These properties make it useful in conditions characterized by microvascular dysfunction.","oneSentence":"Calcium dobesilate reduces capillary fragility and improves microcirculation by decreasing blood viscosity and enhancing red blood cell deformability.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:29:37.935Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Diabetic retinopathy"},{"name":"Diabetic angiopathy"},{"name":"Venous insufficiency"},{"name":"Hemorrhoids"},{"name":"Microvascular disorders"}]},"trialDetails":[{"nctId":"NCT05272826","phase":"PHASE2","title":"Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients","status":"RECRUITING","sponsor":"Canadian Myeloma Research Group","startDate":"2024-12-12","conditions":"Multiple Myeloma","enrollment":75},{"nctId":"NCT05730036","phase":"PHASE3","title":"A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-09-18","conditions":"Relapsed Refractory Multiple Myeloma (RRMM)","enrollment":410},{"nctId":"NCT00572169","phase":"PHASE3","title":"UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2006-11","conditions":"Multiple Myeloma","enrollment":177},{"nctId":"NCT05720949","phase":"PHASE4","title":"Genicular Nerve Blocks for Anterior Cruciate Ligament Knee Surgery","status":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","startDate":"2023-01-12","conditions":"ACL, Anterior Cruciate Ligament Injuries","enrollment":192},{"nctId":"NCT02813135","phase":"PHASE1, PHASE2","title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-08-03","conditions":"Pediatric Cancer","enrollment":472},{"nctId":"NCT02343042","phase":"PHASE1, PHASE2","title":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2015-10","conditions":"Multiple Myeloma","enrollment":300},{"nctId":"NCT06518551","phase":"PHASE1, PHASE2","title":"Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM","status":"RECRUITING","sponsor":"Omar Nadeem, MD","startDate":"2024-11-01","conditions":"Myeloma, Multiple Myeloma, Refractory Multiple Myeloma","enrollment":49},{"nctId":"NCT06351644","phase":"PHASE1, PHASE2","title":"ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Adriana Rossi","startDate":"2024-10-02","conditions":"Relapsed and/or Refractory Multiple Myeloma","enrollment":2},{"nctId":"NCT05980546","phase":"PHASE4","title":"Genicular and Anterior Femoral Cutaneous Nerve Blocks for Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","startDate":"2023-06-07","conditions":"Total Knee Replacement, Genicular Nerve Block, Opioid Use","enrollment":244},{"nctId":"NCT04037605","phase":"EARLY_PHASE1","title":"Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2020-02-09","conditions":"Sleep Restriction","enrollment":5},{"nctId":"NCT03142893","phase":"PHASE1","title":"Hormonal Mechanisms of Sleep Restriction - Axis Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peter y. Liu","startDate":"2017-05-08","conditions":"Sleep Restriction","enrollment":80},{"nctId":"NCT06763094","phase":"NA","title":"Efficacy of Calcium Dobesilate Versus Tranexamic Acid for Treating Heavy Menstrual Bleeding","status":"NOT_YET_RECRUITING","sponsor":"University of Health Sciences Lahore","startDate":"2025-01-05","conditions":"Menorrhagia, Abnormal Uterine Bleeding","enrollment":100},{"nctId":"NCT04826237","phase":"PHASE4","title":"Oral Statins and Protection From Hearing Loss","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2023-02-09","conditions":"Sudden Sensorineural Hearing Loss","enrollment":100},{"nctId":"NCT03000634","phase":"PHASE2","title":"2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy","status":"WITHDRAWN","sponsor":"University of Arkansas","startDate":"2017-04-01","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT02654990","phase":"PHASE2","title":"Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma","status":"COMPLETED","sponsor":"pharmaand GmbH","startDate":"2016-04-27","conditions":"Multiple Myeloma","enrollment":248},{"nctId":"NCT05095922","phase":"PHASE4","title":"Effect of HMP on Diabetic Microangiopaemia in T2DM","status":"COMPLETED","sponsor":"Affiliated Hospital of Nantong University","startDate":"2023-03-28","conditions":"Diabetes Mellitus, Type 2, Diabetic Angiopathies","enrollment":40},{"nctId":"NCT03151811","phase":"PHASE3","title":"A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide","status":"TERMINATED","sponsor":"Oncopeptides AB","startDate":"2017-06-12","conditions":"Multiple Myeloma","enrollment":495},{"nctId":"NCT03432949","phase":"PHASE4","title":"Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2018-02-23","conditions":"Metastatic Prostate Cancer","enrollment":24},{"nctId":"NCT05007262","phase":"PHASE2","title":"Tangningtongluo Tablet in the Treatment of Non-proliferative Diabetic Retinopathy","status":"UNKNOWN","sponsor":"Guizhou Bailing Group Pharmaceutical Co Ltd","startDate":"2021-08-31","conditions":"Type2 Diabetes, Diabetic Retinopathy","enrollment":240},{"nctId":"NCT00783367","phase":"PHASE2","title":"Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2008-07","conditions":"Follicular Lymphoma, Marginal Zone B-Cell Lymphoma, MALT Lymphoma","enrollment":50},{"nctId":"NCT02654132","phase":"PHASE2","title":"An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-03-18","conditions":"Multiple Myeloma","enrollment":117},{"nctId":"NCT02219581","phase":"PHASE4","title":"Steroids in Total Knee Arthroplasty","status":"TERMINATED","sponsor":"Thomas L Bradbury","startDate":"2014-10-16","conditions":"Postoperative Pain, Inflammation, Osteoarthritis","enrollment":1},{"nctId":"NCT01335399","phase":"PHASE3","title":"Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-08-04","conditions":"Multiple Myeloma","enrollment":748},{"nctId":"NCT03995004","phase":"PHASE1","title":"The Effect of Melatonin on Postoperative Pain Reduction After Orthognathic Surgery","status":"SUSPENDED","sponsor":"The University of Hong Kong","startDate":"2022-10","conditions":"Effect of Drugs","enrollment":87},{"nctId":"NCT01239797","phase":"PHASE3","title":"Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-06-20","conditions":"Lymphoma, Multiple Myeloma","enrollment":646},{"nctId":"NCT01891643","phase":"PHASE3","title":"PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2013-09-30","conditions":"Newly Diagnosed, Previously Untreated Multiple Myeloma","enrollment":23},{"nctId":"NCT02128230","phase":"PHASE2","title":"UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2014-06-10","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT02545907","phase":"PHASE1, PHASE2","title":"A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis","status":"COMPLETED","sponsor":"University College, London","startDate":"2017-09-14","conditions":"Amyloidosis","enrollment":10},{"nctId":"NCT02036502","phase":"PHASE1","title":"A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-02-14","conditions":"Multiple Myeloma","enrollment":77},{"nctId":"NCT00773838","phase":"PHASE2","title":"Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-12-01","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":143},{"nctId":"NCT00439296","phase":"PHASE1, PHASE2","title":"ABT-751 With Chemotherapy for Relapsed Pediatric ALL","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2006-05-22","conditions":"Recurrent Pediatric ALL, Relapsed Pediatric ALL, Acute Lymphoblastic Leukemia","enrollment":9},{"nctId":"NCT01670097","phase":"PHASE2","title":"Dexamethasone Dyspnea Study","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-01","conditions":"Advanced Cancers, Hematologic Disorder, Solid Tumors","enrollment":52},{"nctId":"NCT00642954","phase":"PHASE1","title":"Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-02-13","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":31},{"nctId":"NCT04592081","phase":"PHASE4","title":"Dextenza Within Upper Lid Canaliculus Compared With Lower Lid Canaliculus Following Bilateral Cataract Extraction Surgery With PCIOL.","status":"UNKNOWN","sponsor":"Kerry Assil, MD","startDate":"2020-08-01","conditions":"Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation","enrollment":20},{"nctId":"NCT03515200","phase":"PHASE1","title":"Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2018-04-20","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission","enrollment":12},{"nctId":"NCT00290498","phase":"PHASE2","title":"Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-08-01","conditions":"Lymphoma","enrollment":67},{"nctId":"NCT01549431","phase":"PHASE1","title":"Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Emory University","startDate":"2012-01","conditions":"Multiple Myeloma","enrollment":32},{"nctId":"NCT00038090","phase":"PHASE2, PHASE3","title":"Thalidomide-Dexamethasone for Multiple Myeloma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2000-06","conditions":"Multiple Myeloma","enrollment":83},{"nctId":"NCT01636947","phase":"PHASE4","title":"A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-12","conditions":"Nausea, Vomiting","enrollment":494},{"nctId":"NCT02720510","phase":"PHASE2","title":"A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-06-14","conditions":"Multiple Myeloma","enrollment":6},{"nctId":"NCT00056160","phase":"PHASE3","title":"CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2003-01-01","conditions":"Multiple Myeloma","enrollment":353},{"nctId":"NCT01393964","phase":"PHASE1","title":"Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-01-06","conditions":"Multiple Myeloma","enrollment":35},{"nctId":"NCT00248547","phase":"NA","title":"Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2004-05","conditions":"Cancer","enrollment":40},{"nctId":"NCT01632150","phase":"PHASE2","title":"Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-05","conditions":"Relapsed and/or Refractory Multiple Myeloma","enrollment":51},{"nctId":"NCT01499849","phase":"PHASE3","title":"Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2012-02","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":532},{"nctId":"NCT01204164","phase":"PHASE1","title":"Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies","status":"COMPLETED","sponsor":"Tragara Pharmaceuticals, Inc.","startDate":"2010-08","conditions":"AML, ALL, Blast Crisis","enrollment":120},{"nctId":"NCT01500213","phase":"PHASE3","title":"Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2012-02","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":555},{"nctId":"NCT01500226","phase":"PHASE3","title":"Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2012-02","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":1369},{"nctId":"NCT02362321","phase":"PHASE4","title":"Role of Dexamethasone in the Conservative Treatment of Chronic Subdural Hematoma","status":"TERMINATED","sponsor":"CHU de Quebec-Universite Laval","startDate":"2007-01","conditions":"Hematoma, Subdural, Chronic","enrollment":20},{"nctId":"NCT01241006","phase":"PHASE4","title":"Single Oral Dose of Dexamethasone Versus Five Days of Prednisone in Adult Asthma","status":"COMPLETED","sponsor":"Alameda County Medical Center","startDate":"2011-01","conditions":"Asthma, Reactive Airway Disease","enrollment":376},{"nctId":"NCT02234466","phase":"PHASE2","title":"Preoperative Oral Dexamethasone to Improve Recovery After Surgery","status":"UNKNOWN","sponsor":"University of Manitoba","startDate":"2014-08","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT01033825","phase":"PHASE3","title":"Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2010-01","conditions":"Perennial Allergic Rhinitis","enrollment":310},{"nctId":"NCT00979836","phase":"PHASE3","title":"Calcium Dobesilate for Chronic Venous Wounds","status":"SUSPENDED","sponsor":"Fundacion Iberoamericana Itaca","startDate":"2008-04","conditions":"Ulcer","enrollment":230}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Doxium，H20140641"],"phase":"marketed","status":"active","brandName":"Calcium Dobesilate Capsules","genericName":"Calcium Dobesilate Capsules","companyName":"Affiliated Hospital of Nantong University","companyId":"affiliated-hospital-of-nantong-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Calcium dobesilate reduces capillary fragility and improves microcirculation by decreasing blood viscosity and enhancing red blood cell deformability. Used for Diabetic retinopathy, Diabetic angiopathy, Venous insufficiency.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}